Universitätsmedizin Rostock

Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia (2021) Staiger A, Schroeter ML, Ziegler W, Schölderle T, Anderl-Straub S, Danek A, Duning T, et al. Journal article Direct and indirect costs and cost-driving factors of Tuberous sclerosis complex in children, adolescents, and caregivers: a multicenter cohort study (2021) Grau J, Zollner JP, Schubert-Bast S, Kurlemann G, Hertzberg C, Wiemer-Kruel A, Bast T, et al. Journal article Informal caregiving in amyotrophic lateral sclerosis (Als): A high caregiver burden and drastic consequences on caregivers’ lives (2021) Schischlevskij P, Cordts I, Günther R, Stolte B, Zeller D, Schröter C, Weyen U, et al. Journal article Prescription patterns of antiseizure drugs in tuberous sclerosis complex (TSC)-associated epilepsy: a multicenter cohort study from Germany and review of the literature (2021) Strzelczyk A, Grau J, Bast T, Bertsche A, Bettendorf U, Hahn A, Hartmann H, et al. Journal article, Review article Scoring functions for drug-effect similarity (2021) Struckmann S, Ernst M, Fischer S, Mah N, Fuellen G, Möller S Journal article Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition (2021) Knispel S, Gassenmaier M, Menzies AM, Loquai C, Johnson DB, Franklin C, Gutzmer R, et al. Journal article Generation "Social Media": use of modern media to gain information regarding sports injuries (2021) Enz A, Schöffl VR, Simon M, Back DA, Tischer T, Lutter C Journal article TRABECULAR SUBCHONDRAL BONE ANALYSIS OF THE DISTAL RADIUS AT ULTRA-HIGH FIELD (7T) MRI: COMPARISON WITH 3T MRI AND RADIOGRAPHY (2021) Jarraya M, Heiß R, Duryea J, Nagel AM, Lynch JA, Guermazi A, Weber MA, et al. Conference contribution Adjuvant melanoma treatment: real-world data from the DACH region (2021) Schumann K, Mangana J, Dummer R, Sindrilaru M, Reinhardt L, Meier F, Gutzmer R, et al. Conference contribution Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study (2021) Wockel A, Brucker C, Decker T, Falbrede J, Forstbauer H, Gohler T, Hoffmann O, et al. Conference contribution